tradingkey.logo

Dawnzera Approved In U.S. As First And Only RNA-Targeted Prophylactic Treatment

ReutersAug 21, 2025 4:42 PM

- Ionis Pharmaceuticals Inc IONS.O:

  • DAWNZERA™ (DONIDALORSEN) APPROVED IN THE U.S. AS FIRST AND ONLY RNA-TARGETED PROPHYLACTIC TREATMENT FOR HEREDITARY ANGIOEDEMA

  • IONIS PHARMACEUTICALS INC: DAWNZERA WILL BE AVAILABLE IN U.S. IN COMING DAYS

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI